loader

MiNK Therapeutics Inc.

NASDAQ:INKT
Featured Articles and Interviews
Press Releases

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

MiNK Reports First Quarter 2024 Results

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.

Interactive Chart

×